The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Challenge, 2014Inhibition of PKA as a Mechanism to Reverse LRRK2 Mutation-induced Parkinson's Disease
Study Rationale:
Unraveling the role of LRRK2 mutations in disease remains a critical question in Parkinson’s research. The high expression of LRRK2 protein in part of the brain called the striatum... -
Target Validation, 20145-alpha-reductase Inhibition for the Treatment of Levodopa-induced Dyskinesia
Study Rationale:
Although the cause of levodopa-induced dyskinesia is still unclear, these motor complications appear to be due to abnormal dopamine transmission in the brain. Compelling evidence has... -
Research Grant, 2014Evaluation of mGlu4 Positive Allosteric Modulators in Models of Parkinson’s Disease
Study Rationale:
Levodopa and other available treatments for Parkinson’s disease (PD) are initially effective but have unpredictable therapeutic effects and induce serious adverse... -
Therapeutic Pipeline Program, 2014Liver X Receptor Agonists as Novel Therapeutics for Parkinson’s Disease
Study Rationale:
Inflammation is an early and characteristic feature of Parkinson’s disease. Recent studies connect a protein called the liver X receptor (LXR) to inflammation in key... -
Target Validation, 2014Dual GluK1/GluK3 Antagonism as a Neuroprotective Target
Objective/Rationale:
Over activation of glutamate receptors may contribute to the loss of dopamine cells in Parkinson’s disease (PD). Research suggests that drugs that target these... -
Rapid Response Innovation Awards, 2014Neuroimaging Carriers of the Alpha-synuclein E46K Mutation as a Model of Idiopathic Lewy Body Disease
Study Rationale:
In 2004 our group described, for the first time in literature, the E46K mutation of the alpha-synuclein gene in a family from the Basque region of Spain. The rare E46K mutation is...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.